Evolving for sustained growth

For nearly four decades, from our first API sale in the mid-1980s to emerging as a trusted partner for the development and commercialisation of new molecules, we have constantly reinvented ourselves, focussing on building the right capabilities to win in changing market conditions.

Period Focus Achievements and Activities
1984-2013 Building our reputation as a quality-focussed organization
  • Large volume generic APIs and intermediates manufacturing
  • Two US FDA-approved manufacturing facilities and a dedicated R&D centre
  • 3 cGMP manufacturing facilities
  • Developed reputation as a reliable supplier with top global generics formulators
  • Strategic alignment of business towards niche APIs and custom manufacturing solutions
2013-2022 Building a portfolio of differentiated products and business
  • Specialty APIs manufacturing
  • Organic growth of Custom Manufacturing Solutions business – the emergence of strategy with a focus on biotech companies
  • R&D facility approved by US FDA
  • Emphasis on uninterrupted supply and quality
  • Acquisition of advanced intermediates and API facility
2022 onwards Accelerating growth and fortifying for a stronger future
  • Strong performance in the CMS business
  • Over 75 live commercial and development projects
  • Strengthening capabilities and capacities
  • Growing our reputation as a partner for biotech companies
  • Project and customer management
  • Building our GDS pipeline with a focus on technology differentiation including peptides
  • Maintaining leadership position in key molecules
  • Lifecycle management of commercial products
  • Crossed ₹1,000 crores revenue

Evolving our revenue mix

Evolution of GDS Vertical

  • Focus on large volume products with portfolio dictated by customers
  • Shift in focus to differentiated/specialty products with a selective portfolio approach
  • Explored modification of product and customer mix
  • Established a portfolio of diverse drug classes with market leadership in inhalation products a new oral anticoagulant (NOACs), among others
2022 onwards
  • Building a strategic portfolio with products differentiated on technology including generic peptides

Evolution of CMS Vertical

  • Laying the business foundation
  • Leveraging our GDS portfolio for relationships
  • Offering custom synthesis services
  • Laying the building blocks for peptide business
  • Partnering with small biotech companies having late-stage candidates
2020 onwards
  • Continuing to target lucrative early and late-stage clinical candidates
  • Building new capabilities and strategic partnerships